Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $179,734,381 | $181,740,306 | $159,081,426 | $145,789,080 |
| - Cash | $45,471,000 | $29,650,000 | $24,257,000 | $32,830,000 |
| + Debt | $230,983,000 | $202,356,000 | $173,065,000 | $144,128,000 |
| Enterprise Value | $365,246,381 | $354,446,306 | $307,889,426 | $257,087,080 |
| Revenue | $259,594,000 | $227,934,000 | $208,859,000 | $165,615,000 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Gross Profit | $94,729,000 | $81,383,000 | $72,714,000 | $70,186,000 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| EBITDA | $48,056,000 | $43,294,000 | $24,924,000 | $29,492,000 |
| % Margin | 18.5% | 19% | 11.9% | 17.8% |
| Net Income | $18,986,000 | $16,173,000 | $2,201,000 | $15,914,000 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS Diluted | 385.71 | 328.59 | 44.72 | 316.19 |
| % Growth | 17.4% | 634.8% | -85.9% | – |
| Operating Cash Flow | $23,401,000 | $8,212,000 | $2,544,000 | $22,129,000 |
| Capital Expenditures | -$31,223,000 | -$39,325,000 | -$30,469,000 | -$13,576,000 |
| Free Cash Flow | -$7,822,000 | -$31,113,000 | -$27,925,000 | $8,553,000 |